Gemcitabine Plus Vinorelbine Versus Vinorelbine Alone in Elderly Patients With Advanced Non–Small-Cell Lung Cancer
Authors:
- Giuseppe FrasciGFGiuseppe Frasci
- Vito LorussoVLVito Lorusso
- Nicola PanzaNPNicola Panza
- Pasquale ComellaPCPasquale Comella
- Gianpaolo NicolellaGNGianpaolo Nicolella
- Andrea BiancoABAndrea Bianco
- Giuseppe De CataldisGCGiuseppe De Cataldis
- Annunziato IannelliAIAnnunziato Iannelli
- Domenico BilanciaDBDomenico Bilancia
- Mario BelliMBMario Belli
- Bruno MassiddaBMBruno Massidda
- Francovito PiantedosiFPFrancovito Piantedosi
- 1 July 2000
- journal article
- clinical trial
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 18 (13) , 2529-2536
Abstract
PURPOSE: To evaluate whether the addition of gemcitabine (G) to vinorelbine (V) improves survival and quality of life (QoL) among elderly patients with advanced non–small-cell lung cancer (NSCLC). PATIENTS AND METHODS: Patients with NSCLC aged ≥ 70 years with advanced disease were randomly allocated to receive V 30 mg/m2 on days 1 and 8 every 3 weeks or G 1,200 mg/m2 + V 30 mg/m2 on days 1 and 8 every 3 weeks. The estimated sample size was 120 patients per arm, but an interim analysis of survival was planned based on the first 60 patients per arm. RESULTS: In May 1999, the survival data were analyzed of 120 eligible patients (V group = 60; G + V group = 60) who had been randomized from June 1997 to February 1999. Forty-nine patients had stage IIIB disease, and 71 had stage IV. At a median potential follow-up of 14 months (range, 3 to 22 months), 93 patients had died (G + V group = 41; V group = 52). In the G + V group, median survival time was 29 weeks and projected 1-year survival was 30%; these values were 18 weeks and 13% in the V group. According to multivariate Cox analysis, the risk of death in the G + V arm compared with the V arm was 0.48 (95% confidence interval, 0.29 to 0.79; P < .01). Combination therapy was also associated with a clear delay in symptom and QoL deterioration. The overall response rates were 22% and 15% in the G + V and V groups, respectively. CONCLUSION: In elderly patients with NSCLC, G + V treatment is associated with significantly better survival than is V alone.Keywords
This publication has 23 references indexed in Scilit:
- Effects of Vinorelbine on Quality of Life and Survival of Elderly Patients With Advanced Non-Small-Cell Lung CancerJNCI: Journal of the National Cancer Institute, 1999
- Prevalence of co-morbidity in lung cancer patients and its relationship with treatment: A population-based studyLung Cancer, 1998
- Comorbidity and functional status are independent in older cancer patients.Journal of Clinical Oncology, 1998
- The role of gemcitabine in the treatment of small cell lung cancerLung Cancer, 1997
- 82 Treatment of advanced and disseminated non small lung cancer (NSCLC) in elderly patients: Results of the MIC regimenLung Cancer, 1997
- Vinorelbine is well tolerated and active in the treatment of elderly patients with advanced non-small cell lung cancer. A two-stage phase II studyEuropean Journal of Cancer, 1997
- The National Cancer Data Base report on lung cancerCancer, 1996
- Activity of gemcitabine in patients with non-small cell lung cancer: A multicentre, extended phase II studyEuropean Journal of Cancer, 1996
- Prospective Evaluation of the Feasibility of Cisplatin‐based Chemotherapy for Elderly Lung Cancer Patients with Normal Organ FunctionsJapanese Journal of Cancer Research, 1995
- Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trialsBMJ, 1995